本文關(guān)鍵詞：環(huán)孢素A對高危角膜移植術(shù)患者房水炎癥因子影響及臨床效果研究　出處：《臨床眼科雜志》2016年03期 　論文類型：期刊論文

  更多相關(guān)文章： 環(huán)孢素A 角膜移植 炎癥因子 臨床效果

【摘要】：目的探討環(huán)孢素A對高危角膜移植術(shù)患者房水炎癥因子影響及臨床效果,為高危角膜移植術(shù)患者治療和預(yù)后提供參考。方法分析2013年1月至2014年8月52例在我院行穿透性角膜移植(PKP)患者的臨床資料,對照組采用地塞米松滴眼液進(jìn)行治療,觀察組在對照組治療的基礎(chǔ)上給予環(huán)孢素A滴眼液滴眼治療,并比較兩組患者房水中炎癥因子、VEGF水平改變及治療效果。結(jié)果治療后觀察組房水中TNF-α(t=2.885,P=0.006)、IL-2(t=2.386,P=0.021)、IL-6(t=2.961,P=0.005)、治療總有效率(χ~2=5.223,P=0.022)水平明顯高于對照組,差異均具有統(tǒng)計學(xué)意義(P0.05);對照組患者不良反應(yīng)發(fā)生率(χ~2=6.504,P=0.011)、VEGF(t=7.370,P0.001)明顯高于觀察組,差異具有統(tǒng)計學(xué)意義(P0.05)。經(jīng)過Log-rank檢驗后發(fā)現(xiàn),觀察組患者免疫排斥反應(yīng)率明顯低于對照組,差異具有統(tǒng)計學(xué)意義(1,3.57%vs 6,25%;Log-rankχ~2=4.593,P=0.032)。結(jié)論環(huán)孢素A能夠抑制高危角膜移植患者術(shù)后細(xì)胞因子的釋放和新生血管的形成,可進(jìn)一步提高PKP的治療效果和降低排斥反應(yīng)的發(fā)生,臨床治療安全性較好,可以在臨床治療上加以推廣。
[Abstract]:Objective to investigate the effect of cyclosporine A on the inflammatory factors in aqueous humor of high-risk corneal allograft recipients, and to provide references for the treatment and prognosis of high-risk keratoplasty patients. Methods from January 2013 to August 2014 of 52 cases in our hospital underwent penetrating keratoplasty (PKP) clinical data of the patients in control group were treated with dexamethasone eyedrops for treatment, the observation group was treated with cyclosporin A eyedrops in the treatment based on the treatment in control group, and compared between the two groups in aqueous humor of patients with inflammatory factors, the level of VEGF change and effect of treatment. Results after treatment, the observation group of real water TNF- alpha (t=2.885, P=0.006), IL-2 (t=2.386, P=0.021), IL-6 (t=2.961, P=0.005), the total efficiency of treatment (~2=5.223, P=0.022) was significantly higher than the control group, the differences were statistically significant (P0.05); the incidence of adverse reaction in control group patients (x2 ~2=6.504, P=0.011, VEGF) (t=7.370, P0.001) was significantly higher than the observation group, the difference was statistically significant (P0.05). After Log-rank test, it was found that the immunological rejection rate in the observation group was significantly lower than that in the control group, the difference was statistically significant (1,3.57%vs 6,25%; Log-rank x ~2=4.593, P=0.032). Conclusion cyclosporine A can inhibit the release of cytokines and the formation of neovascularization after high risk keratoplasty. It can further improve the therapeutic effect of PKP and reduce the occurrence of rejection. The clinical treatment is safe and can be promoted in clinical treatment.
【作者單位】： 四川省林業(yè)中心醫(yī)院眼科;四川大學(xué)華西第四醫(yī)院眼科;
【分類號】：R779.65
【正文快照】： 作者單位:610081成都,四川省林業(yè)中心醫(yī)院眼科(李福強(qiáng)、熊雅紅);四川大學(xué)華西第四醫(yī)院眼科(李宇)[臨床眼科雜志,2016,24:203][J Clin Ophthalmol,2016,24:203]穿透性角膜移植術(shù)(penetrating keratoplasty,PKP)是用透明的角膜代替已經(jīng)患者已經(jīng)全層混濁的角膜的一種異體移植的手

【相似文獻(xiàn)】

相關(guān)期刊論文 前9條

1 周鴻雁;溫強(qiáng);馬慶杰;谷樹嚴(yán);高識;柏林;趙艷穎;張文松;董賀;;輻射及環(huán)孢素對高危角膜移植術(shù)后角膜血管內(nèi)皮生長因子表達(dá)的抑制作用[J];眼科研究;2010年07期

2 李漢林;谷晉;周瓊;高桂平;;腺病毒載體介導(dǎo)血管抑素防治兔高危角膜移植術(shù)后新生血管化的實驗研究[J];江西醫(yī)藥;2012年02期

3 陳梅珠,楊麗霞,王慶華,陳國蒼,鄭金樹,余鷹翔;高危角膜移植術(shù)前HLA配型的初步臨床研究[J];中國實用眼科雜志;2003年05期

4 陳梅珠;王慶華;陳國蒼;楊麗霞;鄭金樹;余鷹翔;張春俠;;高危角膜移植術(shù)前HLA配型的初步研究[J];福州總醫(yī)院學(xué)報;2004年01期

5 周煉紅;朱祥祥;邢怡橋;譚錦泉;王炯;;TGF-β_1基因在高危角膜移植術(shù)后對移植排斥反應(yīng)的作用[J];眼科研究;2009年09期

6 黃旭;黃金榮;俞益豐;金奇芳;周文天;;局部使用TNP-470后兔眼房水中藥物分布及對兔高危角膜移植術(shù)后新生血管的影響[J];南昌大學(xué)學(xué)報(醫(yī)學(xué)版);2012年04期

7 謝立信,史偉云,王治宇,劉昭升;前房植入環(huán)孢素A緩釋系統(tǒng)抑制鼠高危角膜移植術(shù)后的免疫排斥反應(yīng)[J];中華眼科雜志;2002年07期

8 史偉云;劉廷;謝立信;王身國;;FK506緩釋系統(tǒng)前房植入抑制兔高危角膜移植術(shù)后的免疫排斥反應(yīng)[J];中華眼科雜志;2006年04期

9 ;[J];;年期

，

本文編號：1338101